Primary Care/Hospitalist
RSSArticles
-
Hormone therapy and AD risk
-
Hormone therapy and VTE risk
-
Pharmacology Update: Teriflunomide Tablets (Aubagio®)
The FDA has approved a second oral drug for the treatment of multiple sclerosis (MS). Teriflunomide, a metabolite of leflunomide and a pyrimidine synthesis inhibitor, is an immunomodulatory agent. It is marketed by Sanofi Aventis as Aubagio. -
Internal Medicine Alert - Full October 29, 2012 Issue in PDF
-
Some Antihypertensives May Raise Lip Cancer Risk
Several commonly used photosensitizing antihypertensive drugs can confer as much as a four-fold increase in the risk of lip cancer when prescribed long-term in non-Hispanic whites. -
Updating the 2000 Published Guidelines for Preventing Episodic Migraine: Is Anyone Listening?
This paper updates the American Headache Society and American Academy of Neurology guidelines for prevention of episodic migraine that were previously published in 2000. -
Spice and Sugar: Curcumin and Type 2 DM
Results of this year-long intervention trial suggest that an ethanolic extract of curcumin could, together with appropriate dietary and lifestyle changes, play a role in slowing the progression from prediabetes to type 2 diabetes. -
Clinical Briefs By Louis Kuritzky, MD
Attenuated CV Benefits of Clopidogrel in Diabetes; Is A1c Always the Best Game in Town to Monitor Type 2 Diabetes? -
Full Integrative Medicine Alert January 2013 Issue in PDF
-
ECG Review: A Helpful Hand from aVR
The 12-lead ECG shown above was obtained from a patient with new-onset chest pain. Where is the acute lesion likely to be?